Abstract
Purpose
Adiponectin (APN) is an adipokine with anti-inflammatory and cytoprotective effects. In this study, the therapeutic effect of APN gene delivery using a polymeric carrier was evaluated in an acute lung injury (ALI) model.
Methods
Polyethylenimine (2 kDa, PEI2K), PEI25K (25 kDa), polyamidoamine (generation 2, PAMG2), dexamethasone-conjugated PEI2k (PEI2K-Dexa), and dexamethasone-conjugated PAMG2 (PAMG2-Dexa) were evaluated in vitro and in vivo as gene carriers. Formation of plasmid DNA (pDNA)/carrier complexes was confirmed by gel retardation and heparin competition assays. Delivery efficiency was measured by a luciferase assay and fluorescence microscopy. In an ALI animal model, pAPN/carrier complexes were delivered by intratracheal administration. Therapeutic effects were evaluated by cytokine assays and hematoxylin and eosin (H&E) staining.
Results
Gel retardation assays showed that PEI2K-Dexa and PAMG2-Dexa formed complexes with pDNA. In L2 lung epithelial cells, PAMG2-Dexa yielded higher transfection efficiency than PEI2K, PAMG2, PEI25K, lipofectamine, and PEI2K-Dexa. In vivo experiments showed that PAMG2-Dexa delivered DNA more efficiently to lung tissue than PEI2K-Dexa and PEI25K. Delivery of pAPN/PAMG2-Dexa complexes upregulated APN expression in the lungs of mice with ALI. As a result, the levels of pro-inflammatory cytokines such as TNF-α and IL-1β were decreased. H&E staining showed that inflammation in the lungs of mice with ALI was reduced by delivery of the APN gene.
Conclusion
Delivery of the APN gene using PAMG2-Dexa reduced inflammation in the lungs of mice with ALI. The APN gene could be a useful tool in the development of gene therapy for ALI.
Similar content being viewed by others
Abbreviations
- AdipoR1 and AdipoR2:
-
Adiponectin receptors 1 and 2
- ALI:
-
Acute lung injury
- APN:
-
Adiponectin
- BAL:
-
Bronchoalveolar lavage
- BCA:
-
Bicinchoninic acid
- DMEM:
-
Dulbecco’s modified eagle’s medium
- DMSO:
-
Dimethyl sulfoxide
- DPBS:
-
Dulbecco’s phosphate buffered saline
- ELISA:
-
Enzyme-linked immunosorbent assay
- FBS:
-
Fetal bovine serum
- H&E:
-
Hematoxylin and eosin
- HO-1:
-
Heme oxygenase-1
- IL-1β:
-
Interleukin-1β
- LB:
-
Luria broth
- LPS:
-
Lipopolysaccharide
- MTT:
-
[4,5-dimetylthiazol-2-yl]-2,5 diphenyltetrazoliumbromide
- NF-κB:
-
Nuclear factor-κB
- PAM:
-
Polyamidoamine
- PAMG2-Dexa:
-
Dexamethasone-conjugated PAM generation 2
- pDNA:
-
Plasmid DNA
- PEI2K-Dexa:
-
Dexamethasone-conjugated PEI2K
- PEI:
-
Polyethylenimine
- PFA:
-
Paraformaldehyde
- RLUs:
-
Relative light units
- S1Plyase:
-
Sphingosine-1-phosphate lyase
- siRNA:
-
Small interfering RNA
- TNF-α:
-
Tumor necrosis factor-α
References
Luce JM. Acute lung injury and the acute respiratory distress syndrome. Crit Care Med. 1998;26(2):369–76.
Flori HR, Glidden DV, Rutherford GW, Matthay MA. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med. 2005;171(9):995–1001.
Konter JM, Parker JL, Baez E, Li SZ, Ranscht B, Denzel M, Little FF, Nakamura K, Ouchi N, Fine A, Walsh K, Summer RS. Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. J Immunol. 2012;188(2):854–63.
Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147–63.
Parekh D, Dancer RC, Thickett DR. Acute lung injury. Clin Med (Lond). 2011;11(6):615–8.
Park JH, Kim HA, Park JH, Lee M. Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs. Biomaterials. 2012;33(27):6542–50.
Oh B, Lee M. Combined delivery of HMGB-1 box a peptide and S1PLyase siRNA in animal models of acute lung injury. J Control Release. 2014;175:25–35.
Ahima RS. Central actions of adipocyte hormones. Trends Endocrinol Metab. 2005;16(7):307–13.
Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380(1–2):24–30.
Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301(4):1045–50.
Nigro E, Scudiero O, Sarnataro D, Mazzarella G, Sofia M, Bianco A, Daniele A. Adiponectin affects lung epithelial A549 cell viability counteracting TNFalpha and IL-1ss toxicity through AdipoR1. Int J Biochem Cell Biol. 2013;45(6):1145–53.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83.
Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens). 2012;11(1):8–20.
Walkey AJ, Demissie S, Shah D, Romero F, Puklin L, Summer RS. Plasma adiponectin, clinical factors, and patient outcomes during the acute respiratory distress syndrome. PLoS One. 2014;9(9):e108561.
Shah D, Romero F, Duong M, Wang N, Paudyal B, Suratt BT, Kallen CB, Sun J, Zhu Y, Walsh K, Summer R. Obesity-induced adipokine imbalance impairs mouse pulmonary vascular endothelial function and primes the lung for injury. Sci Rep. 2015;5:11362.
Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther. 2000;7(1):31–4.
Jin L, Zeng X, Liu M, Deng Y, He N. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014;4(3):240–55.
Ibraheem D, Elaissari A, Fessi H. Gene therapy and DNA delivery systems. Int J Pharm. 2014;459(1–2):70–83.
Li SD, Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther. 2006;13(18):1313–9.
Godbey WT, Wu KK, Mikos AG. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res. 1999;45(3):268–75.
Kim HA, Park JH, Lee S, Choi JS, Rhim T, Lee M. Combined delivery of dexamethasone and plasmid DNA in an animal model of LPS-induced acute lung injury. J Control Release. 2011;156(1):60–9.
Kim JY, Ryu JH, Hyun H, Kim HA, Choi JS, Yun Lee D, Rhim T, Park JH, Lee M. Dexamethasone conjugation to polyamidoamine dendrimers G1 and G2 for enhanced transfection efficiency with an anti-inflammatory effect. J Drug Target. 2012;20(8):667–77.
Kim H, Kim HA, Bae YM, Choi JS, Lee M. Dexamethasone-conjugated polyethylenimine as an efficient gene carrier with an anti-apoptotic effect to cardiomyocytes. J Gene Med. 2009;11(6):515–22.
Park JH, Lee M, Kim SW. Non-viral adiponectin gene therapy into obese type 2 diabetic mice ameliorates insulin resistance. J Control Release. 2006;114(1):118–25.
Lee M, Rentz J, Han SO, Bull DA, Kim SW. Water-soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther. 2003;10(7):585–93.
Lee M, Ryu JK, Oh SM, Lee E, Shin HY, Song SU, Kim SW, Suh JK. Water-soluble lipopolymer as a gene carrier to corpus cavernosum. Int J Impot Res. 2005;17(4):326–34.
Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie. 2004;86(11):779–84.
Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–9. quiz 920
Gao C, Liu Y, Yu Q, Yang Q, Li B, Sun L, Yan W, Cai X, Gao E, Xiong L, Wang H, Tao L. TNF-alpha antagonism ameliorates myocardial ischemia-reperfusion injury in mice by upregulating adiponectin. Am J Physiol Heart Circ Physiol. 2015;308(12):H1583–91.
Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005;5(2):129–34.
Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74(1):11–8.
Fujishima Y, Maeda N, Matsuda K, Masuda S, Mori T, Fukuda S, Sekimoto R, Yamaoka M, Obata Y, Kita S, Nishizawa H, Funahashi T, Ranscht B, Shimomura I. Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis. FASEB J. 2017;
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Piao, C., Park, J.H. & Lee, M. Anti-Inflammatory Therapeutic Effect of Adiponectin Gene Delivery Using a Polymeric Carrier in an Acute Lung Injury Model. Pharm Res 34, 1517–1526 (2017). https://doi.org/10.1007/s11095-017-2175-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-017-2175-6